Gracell Biotechnologies Inc.
Rigrodsky Law, P.A. is investigating Gracell Biotechnologies Inc. (“Gracell”) regarding possible breaches of fiduciary duties and other violations of law related to Gracell’s agreement to be acquired by AstraZeneca. Under the terms of the agreement, Gracell shareholders will receive $2.00 per ordinary share in cash plus a non-tradable contingent value right of $0.30 per ordinary share in cash.